Rajith K R Rajoli1, David J Back1, Steve Rannard2, Caren Freel Meyers3, Charles Flexner4, Andrew Owen1, Marco Siccardi5. 1. Department of Molecular and Clinical Pharmacology, University of Liverpool, 70 Pembroke Place, Liverpool, L69 3GF, UK. 2. Department of Chemistry, University of Liverpool, Liverpool, UK. 3. Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA. 4. Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, MD, USA. 5. Department of Molecular and Clinical Pharmacology, University of Liverpool, 70 Pembroke Place, Liverpool, L69 3GF, UK. siccardi@liverpool.ac.uk.
Abstract
BACKGROUND AND OBJECTIVES: Long-acting injectable antiretrovirals represent a pharmacological alternative to oral formulations and an innovative clinical option to address adherence and reduce drug costs. Clinical studies in children and adolescents are characterised by ethical and logistic barriers complicating the identification of dose optimisation. Physiologically-based pharmacokinetic modelling represents a valuable tool to inform dose finding prior to clinical trials. The objective of this study was to simulate potential dosing strategies for existing long-acting injectable depot formulations of cabotegravir and rilpivirine in children and adolescents (aged 3-18 years) using physiologically-based pharmacokinetic modelling. METHODS: Whole-body physiologically-based pharmacokinetic models were developed to represent the anatomical, physiological and molecular processes and age-related changes in children and adolescents through allometric equations. Models were validated for long-acting injectable intramuscular cabotegravir and rilpivirine in adults. Subsequently, the anatomy and physiology of children and adolescents were validated against available literature. The optimal doses of monthly administration of cabotegravir and rilpivirine were identified in children and adolescents, to achieve trough concentrations over the target concentrations derived in a recent efficacy trial of the same formulations. RESULTS: Pharmacokinetic data generated through the physiologically-based pharmacokinetic simulations were similar to observed clinical data in adults. Optimal doses of long-acting injectable antiretrovirals cabotegravir and rilpivirine were predicted using the release rate observed for existing clinical formulations, for different weight groups of children and adolescents. The intramuscular loading dose and maintenance dose of cabotegravir ranged from 200 to 600 mg and from 100 to 250 mg, respectively, and for rilpivirine it ranged from 250 to 550 mg and from 150 to 500 mg, respectively, across various weight groups of children ranging from 15 to 70 kg. CONCLUSIONS: The reported findings represent a rational platform for the identification of suitable dosing strategies and can inform prospective clinical investigation of long-acting injectable formulations in children and adolescents.
BACKGROUND AND OBJECTIVES: Long-acting injectable antiretrovirals represent a pharmacological alternative to oral formulations and an innovative clinical option to address adherence and reduce drug costs. Clinical studies in children and adolescents are characterised by ethical and logistic barriers complicating the identification of dose optimisation. Physiologically-based pharmacokinetic modelling represents a valuable tool to inform dose finding prior to clinical trials. The objective of this study was to simulate potential dosing strategies for existing long-acting injectable depot formulations of cabotegravir and rilpivirine in children and adolescents (aged 3-18 years) using physiologically-based pharmacokinetic modelling. METHODS: Whole-body physiologically-based pharmacokinetic models were developed to represent the anatomical, physiological and molecular processes and age-related changes in children and adolescents through allometric equations. Models were validated for long-acting injectable intramuscular cabotegravir and rilpivirine in adults. Subsequently, the anatomy and physiology of children and adolescents were validated against available literature. The optimal doses of monthly administration of cabotegravir and rilpivirine were identified in children and adolescents, to achieve trough concentrations over the target concentrations derived in a recent efficacy trial of the same formulations. RESULTS: Pharmacokinetic data generated through the physiologically-based pharmacokinetic simulations were similar to observed clinical data in adults. Optimal doses of long-acting injectable antiretrovirals cabotegravir and rilpivirine were predicted using the release rate observed for existing clinical formulations, for different weight groups of children and adolescents. The intramuscular loading dose and maintenance dose of cabotegravir ranged from 200 to 600 mg and from 100 to 250 mg, respectively, and for rilpivirine it ranged from 250 to 550 mg and from 150 to 500 mg, respectively, across various weight groups of children ranging from 15 to 70 kg. CONCLUSIONS: The reported findings represent a rational platform for the identification of suitable dosing strategies and can inform prospective clinical investigation of long-acting injectable formulations in children and adolescents.
Authors: James M Chamberlain; Edmund V Capparelli; Kathleen M Brown; Cheryl W Vance; Kathleen Lillis; Prashant Mahajan; Richard Lichenstein; Rachel M Stanley; Colleen O Davis; Stephen Gordon; Jill M Baren; John N van den Anker Journal: J Pediatr Date: 2011-11-01 Impact factor: 4.406
Authors: R J Kuczmarski; C L Ogden; L M Grummer-Strawn; K M Flegal; S S Guo; R Wei; Z Mei; L R Curtin; A F Roche; C L Johnson Journal: Adv Data Date: 2000-06-08
Authors: David A Margolis; Cynthia C Brinson; Graham H R Smith; Jerome de Vente; Debbie P Hagins; Joseph J Eron; Sandy K Griffith; Marty H St Clair; Marita C Stevens; Peter E Williams; Susan L Ford; Britt S Stancil; Melinda M Bomar; Krischan J Hudson; Kimberly Y Smith; William R Spreen Journal: Lancet Infect Dis Date: 2015-07-19 Impact factor: 25.071
Authors: Naïm Bouazza; Tim R Cressey; Frantz Foissac; Andrzej Bienczak; Paolo Denti; Helen McIlleron; David Burger; Martina Penazzato; Marc Lallemant; Edmund V Capparelli; Jean-Marc Treluyer; Saïk Urien Journal: J Antimicrob Chemother Date: 2016-10-24 Impact factor: 5.790
Authors: Visanou Hansana; Pattara Sanchaisuriya; Jo Durham; Vanphanom Sychareun; Kongmany Chaleunvong; Suwanna Boonyaleepun; Frank Peter Schelp Journal: BMC Public Health Date: 2013-06-28 Impact factor: 3.295
Authors: Rajith K R Rajoli; Paul Curley; Justin Chiong; David Back; Charles Flexner; Andrew Owen; Marco Siccardi Journal: J Infect Dis Date: 2019-05-05 Impact factor: 5.226
Authors: Jordi Minnema; Sven Even F Borgos; Neill Liptrott; Rob Vandebriel; Christiaan Delmaar Journal: Drug Deliv Transl Res Date: 2022-05-12 Impact factor: 5.671